SCHEMBL25584010

SCHEMBL25584010

COC1C(COP(=O)(O)OP(=O)(O)OP(=O)(O)OCC2OC(n3cnc4c(=O)[nH]c(N)nc43)C(OC)C2OP(=O)(O)OCC2OC(n3cnc4c(=O)[nH]c(N)nc43)C(O)C2O)OC(n2c[n+](C)c3c(=O)[nH]c(N)nc32)C1O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.60
FUT5 Q11128 1/20 0.60
KRAS P01116 2/20 0.58
RNASEL Q05823 6/20 0.57
NT5E P21589 1/20 0.56
DCPS Q96C86 1/20 0.56
P2RY6 Q15077 2/20 0.53
P2RY2 P41231 1/20 0.53
P2RY4 P51582 1/20 0.53
P2RX3 P56373 2/20 0.52
ENPP1 P22413 1/20 0.51
P2RY1 P47900 1/20 0.51
P2RX1 P51575 1/20 0.51
P2RY11 Q96G91 1/20 0.51
P2RX4 Q99571 1/20 0.51
IMPDH2 P12268 1/20 0.51
IMPDH1 P20839 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23997752 1.00 TGM2 (0.60) TGM2FUT5KRASRNASELNT5E
SCHEMBL25584006 0.99 TGM2 (0.62) TGM2FUT5KRASRNASELNT5E
SCHEMBL25853904 0.96 TGM2 (0.65) TGM2FUT5KRASRNASELNT5E
SCHEMBL27339951 0.96 TGM2 (0.65) TGM2FUT5KRASRNASELNT5E
SCHEMBL19164501 0.96 TGM2 (0.65) TGM2FUT5KRASRNASELNT5E
SCHEMBL23997728 0.96 TGM2 (0.65) TGM2FUT5KRASRNASELNT5E
SCHEMBL16805257 0.96 TGM2 (0.65) TGM2FUT5KRASRNASELNT5E
SCHEMBL18769340 0.96 TGM2 (0.65) TGM2FUT5KRASRNASELNT5E
SCHEMBL25584016 0.96 RNASEL (0.62) TGM2FUT5RNASELP2RY2P2RX3
SCHEMBL25584009 0.96 RNASEL (0.62) TGM2FUT5RNASELP2RY2P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779659-B2 RNA constructs and uses thereof BioNTech SE (DE) 2023-10-10 US disclosed
US-20230183769-A1 IN VITRO TRANSCRIPTION TECHNOLOGIES BioNTech SE (DE) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11779659-B2 RNA constructs and uses thereof RNGTT, RNMT, NSUN3 TGM2 4235/4885FUT5 1065/4885KRAS 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.